4 Jan 2017 07:00
Realm Therapeutics plc
("Realm Therapeutics", "Realm" or the "Company")
Grant of Options
4 January 2017 - Realm Therapeutics plc (AIM: RLM), an emerging specialty biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, announces the grant of up to 65,000 share options to Ivan Gergel, Non-Executive Director, to subscribe for ordinary shares of 10 pence each (the "Shares") in the capital of the Company (the "Options"). The Options were granted on 3 January 2017 (the "Grant Date"), have an exercise price of 30 pence each and a five-year term.
The grant was made under an individual agreement which is subject to the provisions of the Executive Omnibus Incentive Plan 2016. The Options vest one-third per year on each of the first three anniversaries of the Grant Date.
Following the above grant there is a total of approximately 4.5 million options over ordinary shares outstanding which represents approximately 8.9% of the current issued share capital of the Company.
Enquiries:
Realm Therapeutics plc | +44 (0) 20 3727 1000 |
Alex Martin, Chief Executive Officer | |
Marella Thorell, Chief Financial Officer and Chief Operating Officer | |
FTI Consulting | +44 (0) 20 3727 1000 |
Simon Conway / Mo Noonan | |
N+1 Singer (Nominated Adviser and Broker) | +44 (0) 20 7496 3000 |
Aubrey Powell / Lauren Kettle |
About Realm Therapeutics
Realm Therapeutics is an emerging specialty biopharmaceutical company focused on developing novel immunomodulatory therapies to protect and improve the lives of adults and children. The Company has initiated drug development programmes, based on its proprietary hypochlorous acid technology at high concentrations. The Company believes their formulations have novel immunomodulatory activity with potential application for the treatment of diseases in a number of therapeutic areas including Dermatology and Ophthalmology.
1 | Details of the person discharging managerial responsibilities/person closely associated with them | ||
a) | Name | Ivan Gergel | |
2 | Reason for notification | ||
a) | Position/status | Non-Executive Director | |
b) | Initial notification/Amendment | Initial Notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Realm Therapeutics plc | |
b) | LEI | n/a | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares in Realm Therapeutics plc ISIN: GB00B3XBCR18 | |
b) | Nature of transaction | Grant of options under an individual agreement | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
30 pence | 65,000 | ||
d) | Aggregated information · Aggregated volume · Price | n/a (Single transaction) | |
e) | Date of the transaction | 3 January 2017 | |
f) | Place of the transaction | Outside a trading venue | |
RLM.L (RLM)